Nucleosome‑binding protein HMGN2 exhibits antitumor activity in oral squamous cell carcinoma

Hu,Ankang; Dong,Xiaoqian; Liu,Xiqian; Zhang,Ping; Zhang,Yonghong; Su,Ning; Chen,Qianming; Feng,Yun

doi:10.3892/ol.2013.1665

Nucleosome‑binding protein HMGN2 exhibits antitumor activity in oral squamous cell carcinoma

Authors:
- Ankang Hu
- Xiaoqian Dong
- Xiqian Liu
- Ping Zhang
- Yonghong Zhang
- Ning Su
- Qianming Chen
- Yun Feng
View Affiliations

Affiliations: State Key Laboratory of Oral Diseases, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: November 7, 2013 https://doi.org/10.3892/ol.2013.1665
Pages: 115-120

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Natural killer (NK) cells and cytolytic T lymphocytes (CTLs) serve as effectors in the antitumor response. High mobility group nucleosomal binding domain 2 (HMGN2) is a candidate effector molecule involved in CTL and NK cell function. In the current study, recombinant human HMGN2 was isolated and purified from transformed Escherichia coli. Tca8113 cells, an oral squamous cell carcinoma line, were treated with a variety of HMGN2 protein concentrations and cell growth was analyzed. HMGN2 significantly inhibited the growth of Tca8113 cells and was predicted to arrest cells in the S phase. Moreover, HMGN2 treatment increased the apoptosis rate of Tca8113 cells. Western blotting indicated the upregulation of p53 and Bax proteins, whereas Bcl‑2 was significantly downregulated. In addition, caspase‑3 was found to be activated. Furthermore, the HMGN2 protein may suppress the growth of Tca8113 cells in vivo. The results of the current study indicated that the HMGN2 protein may inhibit the growth of oral squamous cell carcinoma and HMGN2 may represent an antitumor effector molecule of CTL or NK cells.

View Figures

View References

1	Edwards KM, Davis JE, Browne KA, Sutton VR and Trapani JA: Anti-viral strategies of cytotoxic T lymphocytes are manifested through a variety of granule-bound pathways of apoptosis induction. Immunol Cell Biol. 77:76–89. 1999. View Article : Google Scholar
2	Anderson DH, Sawaya MR, Cascio D, Ernst W, Modlin R, Krensky A and Eisenberg D: Granulysin crystal structure and a structure-derived lytic mechanism. J Mol Biol. 325:355–365. 2003. View Article : Google Scholar : PubMed/NCBI
3	Kumar J, Okada S, Clayberger C and Krensky AM: Granulysin: a novel antimicrobial. Expert Opin Investig Drugs. 10:321–329. 2001. View Article : Google Scholar
4	Feng Y, Huang N, Wu Q and Wang B: HMGN2: a novel antimicrobial effector molecule of human mononuclear leukocytes? J Leukoc Biol. 78:1136–1141. 2005. View Article : Google Scholar : PubMed/NCBI
5	Postnikov YV, Herrera JE, Hock R, Scheer U and Bustin M: Clusters of nucleosomes containing chromosomal protein HMG-17 in chromatin1. J Mol Biol. 274:454–465. 1997. View Article : Google Scholar : PubMed/NCBI
6	Srikantha T, Landsman D and Bustin M: Retropseudogenes for human chromosomal protein HMG-17. J Mol Biol. 197:405–413. 1987. View Article : Google Scholar : PubMed/NCBI
7	Spieker N, Beitsma M, van Sluis P, Roobeek I, den Dunnen JT, Speleman F, Caron H and Versteeg R: An integrated 5-Mb physical, genetic, and radiation hybrid map of a 1p36.1 region implicated in neuroblastoma pathogenesis. Gene Chromosomes Cancer. 27:143–152. 2000. View Article : Google Scholar
8	Porkka K, Laakkonen P, Hoffman JA, Bernasconi M and Ruoslahti E: A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci USA. 99:7444–7449. 2002. View Article : Google Scholar : PubMed/NCBI
9	Bustin M: Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol. 19:5237–5246. 1999.PubMed/NCBI
10	Czura CJ, Wang H and Tracey KJ: Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res. 7:315–321. 2001. View Article : Google Scholar : PubMed/NCBI
11	Yang H, Wang H and Tracey KJ: HMG-1 rediscovered as a cytokine. Shock. 15:247–253. 2001. View Article : Google Scholar : PubMed/NCBI
12	Zetterström CK, Strand ML and Söder O: The high mobility group box chromosomal protein 1 is expressed in the human and rat testis where it may function as an antibacterial factor. Hum Reprod. 21:2801–2809. 2006.PubMed/NCBI
13	Fernandes JM, Saint N, Kemp GD and Smith VJ: Oncorhyncin III: a potent antimicrobial peptide derived from the non-histone chromosomal protein H6 of rainbow trout, Oncorhynchus mykiss. Biochem J. 373:621–628. 2003. View Article : Google Scholar
14	Gerlitz G: HMGNs, DNA repair and cancer. Biochim Biophys Acta. 1799:80–85. 2010. View Article : Google Scholar : PubMed/NCBI
15	Birger Y, Ito Y, West KL, Landsman D and Bustin M: HMGN4, a newly discovered nucleosome-binding protein encoded by an intronless gene. DNA Cell Biol. 20:257–264. 2001. View Article : Google Scholar : PubMed/NCBI
16	Bustin M and Reeves R: High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol. 54:35–100. 1996. View Article : Google Scholar
17	West KL, Ito Y, Birger Y, Postnikov Y, Shirakawa H and Bustin M: HMGN3a and HMGN3b, two protein isoforms with a tissue-specific expression pattern, expand the cellular repertoire of nucleosome-binding proteins. J Biol Chem. 276:25959–25969. 2001. View Article : Google Scholar
18	Shirakawa H, Landsman D, Postnikov YV and Bustin M: NBP-45, a novel nucleosomal binding protein with a tissue-specific and developmentally regulated expression. J Biol Chem. 275:6368–6374. 2000. View Article : Google Scholar : PubMed/NCBI
19	Birger Y, Catez F, Furusawa T, Lim JH, Prymakowska-Bosak M, West KL, Postnikov YV, Haines DC and Bustin M: Increased tumorigenicity and sensitivity to ionizing radiation upon loss of chromosomal protein HMGN1. Cancer Res. 65:6711–6718. 2005. View Article : Google Scholar : PubMed/NCBI
20	Rochman M, Malicet C and Bustin M: HMGN5/NSBP1: a new member of the HMGN protein family that affects chromatin structure and function. Biochim Biophys Acta. 1799:86–92. 2010. View Article : Google Scholar : PubMed/NCBI
21	Li DQ, Hou YF, Wu J, Chen Y, Lu JS, Di GH, Ou ZL, Shen ZZ, Ding J and Shao ZM: Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. Eur J Cancer. 42:3274–3286. 2006. View Article : Google Scholar
22	Tang WY, Newbold R, Mardilovich K, Jefferson W, Cheng RY, Medvedovic M and Ho SM: Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. Endocrinology. 149:5922–5931. 2008. View Article : Google Scholar
23	Popescu N, Landsman D and Bustin M: Mapping the human gene coding for chromosomal protein HMG-17. Human Genet. 85:376–378. 1990. View Article : Google Scholar : PubMed/NCBI
24	Okamura S, Ng CC, Koyama K, Takei Y, Arakawa H, Monden M and Nakamura Y: Identification of seven genes regulated by wild-type p53 in a colon cancer cell line carrying a well-controlled wild-type p53 expression system. Oncol Res. 11:281–285. 1999.
25	Bustin M, Reisch J, Einck L and Klippel JH: Autoantibodies to nucleosomal proteins: antibodies to HMG-17 in autoimmune diseases. Science. 215:1245–1247. 1982. View Article : Google Scholar : PubMed/NCBI